(Print or Type Responses)

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APP	ROVAL
OMB Number:	3235-0287
Estimated average	burden
houre par raenones	0.5

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *- Wasman Jane			2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)								
		(First) MACEUTICAL D.		3. Date of Earliest Transaction (Month/Day/Year) 05/23/2019					Officer (give	e title below)	Oth	r (specify below)				
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line)  _X_ Form filed by One Reporting Person  Form filed by More than One Reporting Person							
		NCISCO, CA 9										in med oy	Troite tilling office	reporting reason		
(Cit	y)	(State)	(Zip)			Tab	le I - N	Non-Deriv	ative Securit	ies Acqu	ired, D	Disposed	of, or Bene	ficially Own	d	
1.Title of S (Instr. 3)				2A. Deemed Execution Date,		if Co	Fransa de str. 8)	(A	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				Securities Beneficially ring Reported		Ownership of	Nature Indirect eneficial
				(Month	/Day/Ye		G 1	V A	(A) o		(Instr. 3 and 4)			or Indirect (In	indirect (Instr. 4)	
							Code		mount (D)	Price					Instr. 4)	
D ' 1		separate line for each	i class of securities	beneficia	my owne	airec	tly or i		_							
Reminder:	Report on a s		Table II -					in this f displays	s who respo orm are not s a currently sed of, or Be	require valid C	d to re	espond ontrol n	unless the		ed SEC 14	74 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transac Code	stion of I Second of I Second of I	umber verivat urities uired ( vispose D) tr. 3, 4	nts, or 6. ive Ex (N	in this f displays red, Dispo ptions, con	orm are not s a currently sed of, or Be revertible securisable and Date	require valid C reficially rities)  7. Title of Und Securi	Owne e and A	espond ontrol n ed Amount	unless the umber.	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(	f 10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	ts, calls, 5. Netion of I Sec To Acc To I	warra fumber derivaturities uired (dispose D) tr. 3, 4	nts, op 6. ive Ex (N (A)	in this f displays red, Dispo ptions, con . Date Exe xpiration I	sed of, or Benvertible security and Date (/Year)	require valid C reficially rities)  7. Title of Und Securi	od to report of the composition	espond ontrol n ed Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	f 10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership

# **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Wasman Jane C/O RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	X					

## **Signatures**

/s/ Dolly Vance (Attorney-in-Fact)	05/24/2019
**Signature of Reporting Person	Date

## **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The shares shall vest monthly over one (1) year) from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.